Ionis Pharmaceuticals Key Executives
This section highlights Ionis Pharmaceuticals's key executives, including their titles and compensation details.
Find Contacts at Ionis Pharmaceuticals
( total contacts)
Ionis Pharmaceuticals Earnings
This section highlights Ionis Pharmaceuticals's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-19 | $-1.09 | $-0.66 |
| Read Transcript | Q3 | 2024 | 2024-11-06 | $-1.16 | $-0.95 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $-0.95 | $-0.45 |
| Read Transcript | Q1 | 2024 | 2024-05-07 | $-1.10 | $-0.98 |
| Read Transcript | Q4 | 2023 | 2024-02-21 | $-0.78 | $-0.06 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $-1.01 | $-1.03 |
| Read Transcript | Q2 | 2023 | 2023-08-09 | $-0.94 | $-0.60 |
| Read Transcript | Q1 | 2023 | 2023-05-03 | $-1.00 | $-0.87 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
$33.34
Stock Price
$5.30B
Market Cap
3.00K
Employees
Carlsbad, CA
Location
Financial Statements
Access annual & quarterly financial statements for Ionis Pharmaceuticals, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $705.14M | $787.65M | $587.00M | $810.00M | $729.00M |
| Cost of Revenue | $11.21M | $9.13M | $14.00M | $11.00M | $12.00M |
| Gross Profit | $693.92M | $778.51M | $573.00M | $799.00M | $717.00M |
| Gross Profit Ratio | 98.41% | 98.80% | 97.61% | 98.60% | 98.35% |
| Research and Development Expenses | $901.53M | $899.62M | $833.00M | $643.00M | $535.00M |
| General and Administrative Expenses | $267.50M | $232.60M | $150.30M | $170.90M | $354.00M |
| Selling and Marketing Expenses | $-26.00K | $- | $700.00K | $15.10M | $- |
| Selling General and Administrative Expenses | $267.47M | $232.60M | $151.00M | $186.00M | $354.00M |
| Other Expenses | $- | $- | $3.00M | $9.00M | $2.00M |
| Operating Expenses | $1.17B | $1.13B | $984.00M | $829.00M | $889.00M |
| Cost and Expenses | $1.18B | $1.14B | $998.00M | $840.00M | $901.00M |
| Interest Income | $-6.10M | $- | $25.33M | $10.04M | $30.56M |
| Interest Expense | $84.36M | $- | $8.12M | $4.30M | $44.99M |
| Depreciation and Amortization | $- | $22.50M | $22.11M | $19.56M | $17.16M |
| EBITDA | $-475.08M | $-230.01M | $-227.76M | $-239.00K | $-107.88M |
| EBITDA Ratio | -67.37% | -29.20% | -95.57% | -2.59% | -23.59% |
| Operating Income | $-475.08M | $-353.73M | $-411.00M | $-30.00M | $-172.00M |
| Operating Income Ratio | -67.37% | -44.91% | -70.02% | -3.70% | -23.59% |
| Total Other Income Expenses Net | $15.01M | $19.77M | $152.21M | $1.04M | $37.53M |
| Income Before Tax | $-460.07M | $-333.96M | $-258.00M | $-30.00M | $-170.00M |
| Income Before Tax Ratio | -65.25% | -42.40% | -43.95% | -3.70% | -23.32% |
| Income Tax Expense | $-6.17M | $32.32M | $12.00M | $-1.00M | $317.00M |
| Net Income | $-453.90M | $-366.29M | $-270.00M | $-29.00M | $-487.00M |
| Net Income Ratio | -64.37% | -46.50% | -46.00% | -3.58% | -66.80% |
| EPS | $-3.04 | $-2.56 | $-1.90 | $-0.21 | $-3.49 |
| EPS Diluted | $-3.04 | $-2.56 | $-1.90 | $-0.21 | $-3.49 |
| Weighted Average Shares Outstanding | 149.51M | 143.00M | 141.85M | 141.02M | 139.61M |
| Weighted Average Shares Outstanding Diluted | 149.51M | 143.19M | 141.85M | 141.02M | 139.61M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $226.58M | $134.00M | $225.25M | $119.50M | $324.50M | $144.00M | $188.00M | $131.00M | $152.00M | $159.77M | $133.79M | $141.92M | $440.00M | $133.09M | $125.75M | $111.61M | $290.00M | $160.08M | $145.54M | $133.37M |
| Cost of Revenue | $3.83M | $1.07M | $9.74M | $7.80M | $3.06M | $2.00M | $3.00M | $1.00M | $4.00M | $1.51M | $4.75M | $4.17M | $2.00M | $3.08M | $2.96M | $2.58M | $3.00M | $3.09M | $3.01M | $2.55M |
| Gross Profit | $222.75M | $132.93M | $215.51M | $111.69M | $321.44M | $142.00M | $185.00M | $130.00M | $148.00M | $158.25M | $129.05M | $137.75M | $438.00M | $130.01M | $122.79M | $109.03M | $287.00M | $156.99M | $142.53M | $130.82M |
| Gross Profit Ratio | 98.31% | 99.20% | 95.70% | 93.50% | 99.10% | 98.60% | 98.40% | 99.20% | 97.40% | 99.10% | 96.50% | 97.10% | 99.50% | 97.70% | 97.60% | 97.70% | 98.97% | 98.07% | 97.93% | 98.09% |
| Research and Development Expenses | $245.49M | $219.76M | $222.06M | $214.22M | $256.56M | $215.00M | $230.00M | $198.00M | $308.00M | $182.99M | $180.76M | $161.13M | $179.00M | $184.77M | $139.31M | $139.80M | $171.00M | $125.08M | $122.26M | $116.95M |
| General and Administrative Expenses | $88.10M | $61.60M | $- | $52.64M | $71.00M | $70.00M | $46.10M | $45.52M | $102.30M | $34.40M | $33.80M | $34.10M | $38.60M | $30.10M | $45.10M | $57.10M | $139.00M | $68.45M | $72.02M | $74.99M |
| Selling and Marketing Expenses | $- | $- | $- | $-5.65M | $-384.00K | $- | $-100.00K | $484.00K | $400.00K | $-400.00K | $- | $- | $-600.00K | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $88.10M | $61.60M | $59.53M | $46.99M | $71.00M | $70.00M | $46.00M | $46.00M | $48.00M | $34.40M | $33.80M | $34.10M | $38.00M | $30.10M | $45.10M | $57.10M | $139.00M | $68.45M | $72.02M | $74.99M |
| Other Expenses | $-21.00K | $- | $610.00K | $277.00K | $399.00K | $20.00M | $32.00M | $17.00M | $14.00M | $4.71M | $-12.30M | $187.00K | $4.00M | $-469.00K | $-189.00K | $3.00K | $-1.00M | $126.00K | $-149.00K | $-99.00K |
| Operating Expenses | $333.57M | $281.40M | $281.60M | $261.21M | $327.56M | $285.00M | $276.00M | $244.00M | $356.00M | $217.39M | $214.56M | $195.23M | $217.00M | $214.87M | $184.41M | $196.90M | $310.00M | $193.53M | $194.28M | $191.95M |
| Cost and Expenses | $337.40M | $282.47M | $291.34M | $269.01M | $330.62M | $287.00M | $279.00M | $245.00M | $360.00M | $218.91M | $219.30M | $199.40M | $219.00M | $217.95M | $187.36M | $199.48M | $313.00M | $196.62M | $197.29M | $194.49M |
| Interest Income | $-1.60M | $2.23M | $- | $49.00K | $3.28M | $23.93M | $20.79M | $18.63M | $11.88M | $7.52M | $30.00K | $- | $149.00K | $40.00K | $377.00K | $14.00K | $- | $- | $- | $8.27M |
| Interest Expense | $21.27M | $21.23M | $22.79M | $20.56M | $20.85M | $18.00M | $18.00M | $16.00M | $5.72M | $800.00K | $800.00K | $800.00K | $2.24M | $2.34M | $- | $1.50M | $11.51M | $11.32M | $11.17M | $- |
| Depreciation and Amortization | $5.27M | $23.66M | $5.58M | $5.65M | $5.61M | $5.59M | $5.69M | $5.61M | $7.03M | $5.09M | $5.09M | $4.89M | $4.98M | $4.71M | $5.01M | $4.86M | $4.57M | $4.45M | $4.03M | $4.11M |
| EBITDA | $-80.50M | $-125.00M | $-37.84M | $-114.97M | $25.17M | $-113.23M | $-51.81M | $-90.21M | $-35.24M | $-39.48M | $-95.66M | $-57.50M | $232.53M | $-78.73M | $-73.18M | $-82.47M | $-8.97M | $-24.67M | $-29.00M | $-46.63M |
| EBITDA Ratio | -35.53% | -93.28% | -26.86% | -120.39% | -0.51% | -85.42% | -31.38% | -74.05% | -235.53% | -31.72% | -70.30% | -37.87% | 50.23% | -60.57% | -45.12% | -75.20% | -7.93% | -19.96% | -32.89% | -42.82% |
| Operating Income | $-110.82M | $-148.66M | $-66.09M | $-149.51M | $-6.12M | $-143.00M | $-91.00M | $-114.00M | $-208.00M | $-59.14M | $-85.51M | $-57.48M | $221.00M | $-85.85M | $-72.97M | $-91.97M | $-23.00M | $-36.54M | $-51.75M | $-61.13M |
| Operating Income Ratio | -48.91% | -110.94% | -29.34% | -125.12% | -1.89% | -99.31% | -48.40% | -87.02% | -136.84% | -37.02% | -63.91% | -40.50% | 50.23% | -64.50% | -58.03% | -82.41% | -7.93% | -22.82% | -35.56% | -45.83% |
| Total Other Income Expenses Net | $3.78M | $4.55M | $-110.00K | $6.79M | $3.36M | $2.46M | $12.75M | $1.21M | $163.69M | $12.45M | $-17.36M | $-6.57M | $4.00M | $2.08M | $-7.58M | $2.23M | $-1.33M | $4.99M | $16.28M | $8.17M |
| Income Before Tax | $-107.04M | $-144.10M | $-66.20M | $-142.73M | $-2.77M | $-141.00M | $-77.00M | $-113.00M | $-44.00M | $-46.71M | $-102.88M | $-64.07M | $225.00M | $-83.77M | $-80.55M | $-89.74M | $-24.00M | $-40.44M | $-44.21M | $-61.74M |
| Income Before Tax Ratio | -47.24% | -107.54% | -29.39% | -119.44% | -0.85% | -97.92% | -40.96% | -86.26% | -28.95% | -29.24% | -76.89% | -45.15% | 51.14% | -62.94% | -64.05% | -80.41% | -8.28% | -25.26% | -30.38% | -46.29% |
| Income Tax Expense | $-2.69M | $-4.00M | $64.00K | $75.00K | $6.50M | $6.00M | $8.00M | $11.00M | $8.00M | $283.00K | $2.26M | $1.09M | $303.00K | $-1.31M | $327.00K | $130.00K | $318.00M | $2.65M | $-439.00K | $-3.26M |
| Net Income | $-104.35M | $-140.48M | $-66.27M | $-142.80M | $-9.26M | $-147.00M | $-85.00M | $-124.00M | $-52.00M | $-46.99M | $-105.14M | $-65.17M | $225.00M | $-82.47M | $-80.88M | $-89.87M | $-340.00M | $-30.94M | $-31.84M | $-48.23M |
| Net Income Ratio | -46.05% | -104.84% | -29.42% | -119.50% | -2.85% | -102.08% | -45.21% | -94.66% | -34.21% | -29.41% | -78.58% | -45.92% | 51.14% | -61.96% | -64.31% | -80.52% | -117.24% | -19.33% | -21.88% | -36.16% |
| EPS | $-0.70 | $-0.95 | $-0.45 | $-0.98 | $-0.06 | $-1.03 | $-0.59 | $-0.87 | $-0.37 | $-0.33 | $-0.74 | $-0.46 | $1.59 | $-0.58 | $-0.57 | $-0.64 | $-2.43 | $-0.22 | $-0.23 | $-0.35 |
| EPS Diluted | $-0.70 | $-0.95 | $-0.45 | $-0.98 | $-0.06 | $-1.03 | $-0.59 | $-0.87 | $-0.37 | $-0.33 | $-0.74 | $-0.46 | $1.41 | $-0.58 | $-0.57 | $-0.64 | $-2.43 | $-0.22 | $-0.23 | $-0.35 |
| Weighted Average Shares Outstanding | 149.51M | 148.59M | 145.96M | 145.54M | 144.00M | 143.32M | 143.10M | 142.74M | 142.00M | 141.95M | 141.79M | 141.60M | 141.00M | 141.14M | 140.96M | 140.77M | 139.96M | 139.71M | 139.35M | 139.43M |
| Weighted Average Shares Outstanding Diluted | 149.51M | 148.59M | 145.96M | 145.54M | 144.00M | 143.32M | 143.10M | 142.74M | 142.00M | 141.95M | 141.79M | 141.60M | 160.00M | 141.14M | 140.96M | 140.77M | 140.00M | 139.71M | 139.35M | 139.43M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $242.08M | $399.27M | $1.99B | $2.12B | $1.89B |
| Short Term Investments | $2.06B | $1.93B | $1.71B | $1.25B | $1.49B |
| Cash and Short Term Investments | $2.30B | $2.33B | $1.99B | $2.12B | $1.89B |
| Net Receivables | $92.19M | $97.78M | $25.54M | $61.90M | $76.20M |
| Inventory | $12.51M | $28.43M | $22.03M | $24.81M | $21.96M |
| Other Current Assets | $217.93M | $184.45M | $157.72M | $125.17M | $140.16M |
| Total Current Assets | $2.62B | $2.64B | $2.20B | $2.35B | $2.13B |
| Property Plant Equipment Net | $256.11M | $242.94M | $256.00M | $178.00M | $181.00M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $29.00M | $27.94M |
| Goodwill and Intangible Assets | $- | $- | $- | $29.00M | $27.94M |
| Long Term Investments | $- | $42.99M | $40.37M | $15.62M | $15.06M |
| Tax Assets | $- | $- | $- | $-15.62M | $-15.06M |
| Other Non-Current Assets | $127.28M | $62.29M | $34.63M | $59.99M | $51.06M |
| Total Non-Current Assets | $383.38M | $348.22M | $331.00M | $267.00M | $260.00M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $3.00B | $2.99B | $2.53B | $2.61B | $2.39B |
| Account Payables | $42.96M | $26.03M | $17.92M | $11.90M | $17.20M |
| Short Term Debt | $- | $53.16M | $7.54M | $3.53M | $308.81M |
| Tax Payables | $34.00K | $2.15M | $6.25M | $36.00K | $1.32M |
| Deferred Revenue | $78.99M | $151.13M | $91.00M | $98.00M | $108.00M |
| Other Current Liabilities | $187.33M | $215.62M | $189.28M | $127.37M | $163.19M |
| Total Current Liabilities | $309.32M | $448.09M | $312.00M | $241.00M | $290.00M |
| Long Term Debt | $1.41B | $1.91B | $1.36B | $1.18B | $623.53M |
| Deferred Revenue Non-Current | $- | $241.18M | $288.00M | $352.00M | $424.00M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $698.72M | $- | $- | $67.09M | $- |
| Total Non-Current Liabilities | $2.11B | $2.16B | $1.65B | $1.60B | $1.26B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $2.42B | $2.60B | $1.96B | $1.84B | $1.55B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $158.00K | $144.00K | $142.00K | $141.00K | $140.00K |
| Retained Earnings | $-2.25B | $-1.80B | $-1.43B | $-1.16B | $-1.25B |
| Accumulated Other Comprehensive Income Loss | $-30.81M | $-32.65M | $-57.48M | $-32.67M | $-21.07M |
| Other Total Stockholders Equity | $2.87B | $2.22B | $2.06B | $1.96B | $1.90B |
| Total Stockholders Equity | $588.35M | $386.69M | $573.00M | $772.00M | $843.00M |
| Total Equity | $588.35M | $386.69M | $573.00M | $772.00M | $843.00M |
| Total Liabilities and Stockholders Equity | $3.00B | $2.99B | $2.53B | $2.61B | $2.39B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.00B | $2.99B | $2.53B | $2.61B | $2.39B |
| Total Investments | $2.06B | $1.98B | $1.71B | $1.25B | $1.49B |
| Total Debt | $1.41B | $1.45B | $1.34B | $1.16B | $749.00M |
| Net Debt | $1.17B | $1.05B | $-642.00M | $-954.00M | $-1.14B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $242.08M | $334.61M | $293.99M | $348.89M | $399.27M | $352.06M | $424.79M | $309.03M | $1.99B | $314.99M | $521.92M | $542.51M | $2.12B | $632.95M | $565.12M | $414.15M | $1.89B | $633.06M | $530.18M | $486.19M |
| Short Term Investments | $2.06B | $2.15B | $1.78B | $1.86B | $1.93B | $1.88B | $1.96B | $2.04B | $1.71B | $1.67B | $1.50B | $1.51B | $1.25B | $1.35B | $1.49B | $1.41B | $1.49B | $1.70B | $1.82B | $1.90B |
| Cash and Short Term Investments | $2.30B | $2.48B | $2.08B | $2.21B | $2.33B | $2.24B | $2.38B | $2.35B | $1.99B | $1.98B | $2.02B | $2.05B | $2.12B | $1.99B | $2.06B | $1.82B | $1.89B | $2.33B | $2.35B | $2.38B |
| Net Receivables | $92.19M | $17.93M | $27.26M | $5.14M | $97.78M | $142.36M | $27.96M | $13.91M | $25.54M | $6.64M | $6.75M | $26.12M | $61.90M | $9.07M | $24.00M | $23.40M | $76.20M | $38.98M | $27.83M | $28.61M |
| Inventory | $12.51M | $28.45M | $28.72M | $30.26M | $28.43M | $25.63M | $25.54M | $22.20M | $22.03M | $20.64M | $19.81M | $24.03M | $24.81M | $22.93M | $24.10M | $22.20M | $21.96M | $22.17M | $23.72M | $22.89M |
| Other Current Assets | $217.93M | $184.19M | $194.72M | $174.06M | $184.45M | $181.07M | $177.87M | $152.34M | $157.72M | $143.17M | $142.76M | $127.11M | $125.17M | $136.64M | $131.04M | $123.83M | $140.16M | $146.63M | $131.01M | $122.47M |
| Total Current Assets | $2.62B | $2.71B | $2.33B | $2.42B | $2.64B | $2.58B | $2.62B | $2.54B | $2.20B | $2.15B | $2.19B | $2.25B | $2.35B | $2.16B | $2.24B | $1.99B | $2.13B | $2.54B | $2.53B | $2.56B |
| Property Plant Equipment Net | $256.11M | $246.93M | $242.84M | $242.23M | $242.94M | $245.00M | $269.00M | $264.00M | $256.00M | $180.81M | $177.01M | $177.72M | $178.00M | $180.14M | $179.32M | $180.41M | $181.00M | $181.52M | $172.62M | $163.95M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.61M | $29.05M | $29.30M | $29.00M | $30.04M | $29.37M | $28.80M | $27.94M | $28.27M | $27.70M | $26.75M |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.61M | $29.05M | $29.30M | $29.00M | $30.04M | $29.37M | $28.80M | $27.94M | $28.27M | $27.70M | $26.75M |
| Long Term Investments | $- | $- | $41.02M | $42.99M | $42.99M | $42.99M | $42.99M | $42.99M | $40.37M | $40.37M | $40.37M | $39.82M | $15.62M | $32.32M | $15.06M | $15.06M | $15.06M | $24.35M | $24.34M | $15.02M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-40.37M | $-40.37M | $-39.82M | $-15.62M | $-32.32M | $-15.06M | $-15.06M | $-15.06M | $307.74M | $305.98M | $309.61M |
| Other Non-Current Assets | $127.28M | $120.32M | $77.88M | $63.04M | $62.29M | $61.01M | $43.01M | $35.01M | $34.63M | $59.43M | $58.92M | $58.95M | $59.99M | $48.97M | $49.96M | $49.92M | $51.06M | $16.84M | $17.13M | $17.53M |
| Total Non-Current Assets | $383.38M | $367.25M | $361.75M | $348.25M | $348.22M | $349.00M | $355.00M | $342.00M | $331.00M | $269.85M | $264.99M | $265.97M | $267.00M | $259.15M | $258.65M | $259.13M | $260.00M | $558.72M | $547.76M | $532.87M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.00B | $3.08B | $2.69B | $2.76B | $2.99B | $2.93B | $2.97B | $2.88B | $2.53B | $2.42B | $2.46B | $2.52B | $2.61B | $2.41B | $2.50B | $2.25B | $2.39B | $3.10B | $3.08B | $3.09B |
| Account Payables | $42.96M | $9.05M | $9.24M | $13.08M | $26.03M | $5.62M | $24.02M | $10.50M | $17.92M | $20.55M | $10.35M | $16.12M | $11.90M | $8.36M | $14.66M | $9.51M | $17.20M | $16.22M | $7.41M | $21.17M |
| Short Term Debt | $9.28M | $44.47M | $44.42M | $44.38M | $53.16M | $41.02M | $- | $11.32M | $7.54M | $4.97M | $- | $- | $3.53M | $61.94M | $69.85M | $69.50M | $316.11M | $5.85M | $4.97M | $4.15M |
| Tax Payables | $34.00K | $41.00K | $284.00K | $2.21M | $2.15M | $31.07M | $24.73M | $17.29M | $6.25M | $16.00K | $14.00K | $901.00K | $36.00K | $450.00K | $1.88M | $1.33M | $1.32M | $8.93M | $27.94M | $32.95M |
| Deferred Revenue | $78.99M | $76.02M | $94.07M | $130.41M | $151.13M | $205.00M | $96.00M | $92.00M | $91.00M | $99.51M | $93.39M | $91.44M | $98.00M | $97.92M | $102.07M | $106.74M | $108.00M | $104.43M | $100.40M | $120.81M |
| Other Current Liabilities | $178.05M | $174.99M | $158.15M | $137.57M | $215.62M | $152.75M | $142.97M | $130.86M | $189.28M | $158.41M | $164.05M | $119.99M | $127.37M | $111.11M | $105.37M | $108.03M | $-44.63M | $109.14M | $90.62M | $78.94M |
| Total Current Liabilities | $309.32M | $304.57M | $306.16M | $327.65M | $448.09M | $917.00M | $798.00M | $764.00M | $312.00M | $283.45M | $267.81M | $228.45M | $241.00M | $279.78M | $293.82M | $295.11M | $290.00M | $244.57M | $231.34M | $258.02M |
| Long Term Debt | $1.41B | $1.40B | $1.93B | $1.92B | $1.91B | $1.97B | $2.00B | $1.36B | $1.36B | $1.23B | $1.23B | $1.23B | $1.18B | $1.22B | $1.22B | $851.82M | $623.53M | $814.82M | $804.24M | $734.71M |
| Deferred Revenue Non-Current | $156.50M | $- | $188.70M | $215.09M | $241.18M | $249.00M | $254.00M | $273.00M | $288.00M | $294.66M | $315.20M | $333.14M | $352.00M | $362.89M | $379.87M | $401.97M | $424.00M | $429.93M | $448.58M | $467.84M |
| Deferred Tax Liabilities Non-Current | $- | $- | $-1.73B | $-356.40M | $- | $- | $- | $-505.08M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $542.21M | $711.88M | $- | $- | $- | $- | $- | $778.05M | $- | $20.90M | $22.30M | $22.30M | $67.09M | $21.63M | $18.20M | $19.10M | $633.47M | $- | $- | $59.93M |
| Total Non-Current Liabilities | $2.11B | $2.11B | $2.12B | $2.14B | $2.16B | $1.70B | $1.75B | $1.63B | $1.65B | $1.54B | $1.56B | $1.58B | $1.60B | $1.60B | $1.62B | $1.27B | $1.26B | $1.24B | $1.25B | $1.26B |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $2.42B | $2.42B | $2.43B | $2.47B | $2.60B | $2.62B | $2.54B | $2.40B | $1.96B | $1.83B | $1.83B | $1.81B | $1.84B | $1.88B | $1.91B | $1.57B | $1.55B | $1.49B | $1.48B | $1.52B |
| Preferred Stock | $- | $- | $2.04B | $- | $32.65M | $- | $- | $- | $- | $- | $- | $- | $263.00K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $158.00K | $158.00K | $146.00K | $146.00K | $144.00K | $143.00K | $143.00K | $143.00K | $142.00K | $142.00K | $142.00K | $142.00K | $141.00K | $141.00K | $141.00K | $141.00K | $140.00K | $140.00K | $139.00K | $139.00K |
| Retained Earnings | $-2.25B | $-2.15B | $-2.00B | $-1.94B | $-1.80B | $-1.79B | $-1.64B | $-1.55B | $-1.43B | $-1.38B | $-1.33B | $-1.23B | $-1.16B | $-1.38B | $-1.30B | $-1.22B | $-1.25B | $-909.10M | $-878.15M | $-846.31M |
| Accumulated Other Comprehensive Income Loss | $-30.81M | $-24.17M | $-34.84M | $-34.96M | $-32.65M | $-46.04M | $-50.91M | $-48.98M | $-57.48M | $-63.14M | $-54.01M | $-48.58M | $-32.67M | $-27.44M | $-25.80M | $-24.20M | $-21.07M | $-19.57M | $-16.44M | $-27.23M |
| Other Total Stockholders Equity | $2.87B | $2.83B | $2.30B | $2.27B | $2.22B | $2.15B | $2.12B | $2.09B | $2.06B | $2.03B | $2.01B | $1.98B | $1.96B | $1.94B | $1.91B | $1.93B | $1.90B | $2.31B | $2.27B | $2.23B |
| Total Stockholders Equity | $588.35M | $662.47M | $263.70M | $296.51M | $386.69M | $315.00M | $428.00M | $487.00M | $573.00M | $594.36M | $624.73M | $709.57M | $772.00M | $530.54M | $582.67M | $680.56M | $843.00M | $1.38B | $1.38B | $1.36B |
| Total Equity | $588.35M | $662.47M | $263.70M | $296.51M | $386.69M | $315.00M | $428.00M | $487.00M | $573.00M | $594.36M | $624.73M | $709.57M | $772.00M | $530.54M | $582.67M | $680.56M | $843.00M | $1.61B | $1.59B | $1.57B |
| Total Liabilities and Stockholders Equity | $3.00B | $3.08B | $2.69B | $2.76B | $2.99B | $2.93B | $2.97B | $2.88B | $2.53B | $2.42B | $2.46B | $2.52B | $2.61B | $2.41B | $2.50B | $2.25B | $2.39B | $3.10B | $3.08B | $3.09B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $223.24M | $217.62M | $210.17M |
| Total Liabilities and Total Equity | $3.00B | $3.08B | $2.69B | $2.76B | $2.99B | $2.93B | $2.97B | $2.88B | $2.53B | $2.42B | $2.46B | $2.52B | $2.61B | $2.41B | $2.50B | $2.25B | $2.39B | $3.10B | $3.08B | $3.09B |
| Total Investments | $2.06B | $2.15B | $1.83B | $1.90B | $1.98B | $1.88B | $1.96B | $2.04B | $1.71B | $1.67B | $1.50B | $1.51B | $1.25B | $1.35B | $1.49B | $1.41B | $1.49B | $1.70B | $1.82B | $1.90B |
| Total Debt | $1.42B | $1.45B | $1.98B | $1.97B | $1.45B | $1.40B | $1.47B | $1.36B | $1.34B | $1.22B | $1.22B | $1.22B | $1.16B | $1.28B | $1.28B | $909.79M | $749.00M | $798.93M | $789.18M | $779.59M |
| Net Debt | $1.17B | $1.11B | $1.68B | $1.62B | $1.05B | $1.05B | $1.05B | $1.05B | $-642.00M | $909.40M | $701.39M | $679.71M | $-954.00M | $649.05M | $715.40M | $495.63M | $-1.14B | $165.87M | $259.00M | $293.40M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-453.90M | $-366.29M | $-269.72M | $-28.60M | $-486.77M |
| Depreciation and Amortization | $19.65M | $22.50M | $22.11M | $19.56M | $17.16M |
| Deferred Income Tax | $- | $- | $- | $25.31M | $313.27M |
| Stock Based Compensation | $130.20M | $105.81M | $100.26M | $120.68M | $230.12M |
| Change in Working Capital | $-209.39M | $-77.26M | $7.57M | $-113.82M | $-73.56M |
| Accounts Receivables | $- | $-72.06M | $36.36M | $5.05M | $-22.00M |
| Inventory | $-5.07M | $-6.39M | $2.77M | $-2.84M | $-1.26M |
| Accounts Payables | $15.99M | $8.12M | $1.09M | $-6.00M | $-2.75M |
| Other Working Capital | $-220.31M | $-6.93M | $-32.65M | $-110.03M | $-47.54M |
| Other Non Cash Items | $12.49M | $7.73M | $-134.59M | $7.67M | $35.66M |
| Net Cash Provided by Operating Activities | $-500.95M | $-307.51M | $-274.37M | $30.80M | $35.89M |
| Investments in Property Plant and Equipment | $-45.28M | $-23.80M | $-20.10M | $-17.90M | $-41.05M |
| Acquisitions Net | $- | $- | $254.08M | $5.95M | $5.93M |
| Purchases of Investments | $-1.85B | $-1.77B | $-1.49B | $-1.13B | $-1.57B |
| Sales Maturities of Investments | $1.77B | $1.58B | $989.15M | $1.34B | $1.89B |
| Other Investing Activities | $-5.06M | $-4.18M | $254.08M | $-5.95M | $-5.93M |
| Net Cash Used for Investing Activities | $-134.03M | $-214.13M | $-262.64M | $194.91M | $274.48M |
| Debt Repayment | $-44.67M | $86.90M | $-50.69M | $313.57M | $- |
| Common Stock Issued | $522.73M | $49.44M | $6.37M | $11.56M | $52.04M |
| Common Stock Repurchased | $- | $- | $- | $- | $-90.55M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $522.73M | $507.74M | $-10.98M | $-79.20M | $-558.10M |
| Net Cash Used Provided by Financing Activities | $478.06M | $644.08M | $-55.30M | $245.93M | $-596.61M |
| Effect of Forex Changes on Cash | $-273.00K | $352.00K | $-418.00K | $-111.00K | $617.00K |
| Net Change in Cash | $-157.19M | $122.79M | $-592.72M | $471.53M | $-285.62M |
| Cash at End of Period | $242.08M | $399.27M | $276.47M | $869.19M | $397.66M |
| Cash at Beginning of Period | $399.27M | $276.47M | $869.19M | $397.66M | $683.29M |
| Operating Cash Flow | $-500.95M | $-307.51M | $-274.37M | $30.80M | $35.89M |
| Capital Expenditure | $-45.28M | $-28.01M | $-20.10M | $-17.90M | $-41.05M |
| Free Cash Flow | $-546.23M | $-335.52M | $-294.47M | $12.90M | $-5.16M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-104.35M | $-140.48M | $-66.27M | $-142.80M | $-9.26M | $-147.41M | $-85.29M | $-124.32M | $-52.43M | $-46.99M | $-105.14M | $-65.17M | $224.61M | $-82.47M | $-80.88M | $-89.87M | $-341.43M | $-43.09M | $-43.77M | $-58.48M |
| Depreciation and Amortization | $5.27M | $3.62M | $5.58M | $5.65M | $5.61M | $5.59M | $5.69M | $5.61M | $7.03M | $5.09M | $5.09M | $4.89M | $4.98M | $4.71M | $5.01M | $4.86M | $4.57M | $4.45M | $4.03M | $4.11M |
| Deferred Income Tax | $- | $- | $- | $- | $-5.35M | $6.44M | $-19.23M | $- | $- | $- | $- | $- | $4.10M | $4.63M | $12.57M | $4.01M | $316.75M | $-962.00K | $924.00K | $-3.44M |
| Stock Based Compensation | $36.15M | $31.98M | $30.73M | $31.34M | $26.34M | $25.96M | $26.56M | $26.95M | $25.69M | $23.84M | $24.50M | $26.24M | $22.26M | $30.54M | $30.02M | $37.86M | $95.04M | $45.84M | $48.44M | $40.79M |
| Change in Working Capital | $-61.38M | $139.55M | $-94.03M | $-45.52M | $12.99M | $-3.68M | $-31.56M | $-55.00M | $-30.88M | $-9.30M | $51.51M | $-3.76M | $-55.20M | $-14.70M | $-31.32M | $-12.60M | $13.89M | $-29.89M | $-56.58M | $-973.00K |
| Accounts Receivables | $-74.26M | $9.33M | $-22.12M | $92.64M | $44.76M | $-93.51M | $-40.54M | $11.62M | $-18.89M | $106.00K | $19.37M | $35.77M | $-52.92M | $10.95M | $-10.37M | $57.38M | $-29.93M | $-26.36M | $-7.10M | $41.40M |
| Inventory | $-5.04M | $271.00K | $1.54M | $-1.83M | $-2.79M | $-96.00K | $-3.34M | $-167.00K | $-1.39M | $-834.00K | $4.22M | $774.00K | $-1.88M | $1.17M | $-1.90M | $-234.00K | $207.00K | $1.55M | $-837.00K | $-2.18M |
| Accounts Payables | $35.20M | $-2.15M | $-3.19M | $-13.87M | $20.58M | $-17.98M | $15.81M | $-10.29M | $-4.51M | $8.28M | $-5.55M | $2.88M | $4.74M | $-7.92M | $6.75M | $-9.57M | $8.21M | $3.97M | $-15.35M | $411.00K |
| Other Working Capital | $-17.29M | $132.09M | $-70.25M | $-122.45M | $-49.56M | $107.91M | $-3.50M | $-56.17M | $-6.08M | $-16.85M | $33.47M | $-7.41M | $-5.14M | $-18.90M | $-25.80M | $-60.18M | $35.40M | $-9.05M | $-33.29M | $-40.60M |
| Other Non Cash Items | $8.18M | $-149.66M | $4.10M | $-32.90M | $2.55M | $4.07M | $6.47M | $12.78M | $-149.61M | $2.93M | $5.94M | $6.14M | $2.93M | $1.72M | $1.94M | $1.08M | $9.16M | $13.29M | $2.81M | $10.40M |
| Net Cash Provided by Operating Activities | $-116.14M | $-114.99M | $-119.88M | $-149.94M | $32.87M | $-109.02M | $-97.36M | $-133.99M | $-200.19M | $-24.43M | $-18.10M | $-31.65M | $203.69M | $-55.57M | $-62.65M | $-54.66M | $97.98M | $-10.36M | $-44.14M | $-7.58M |
| Investments in Property Plant and Equipment | $-25.50M | $6.21M | $-20.26M | $-5.73M | $819.00K | $-3.24M | $-13.07M | $-11.72M | $-5.01M | $-7.06M | $-4.50M | $-3.53M | $-3.99M | $-4.60M | $-6.31M | $-3.00M | $-6.87M | $-12.97M | $-11.22M | $-9.98M |
| Acquisitions Net | $- | $- | $- | $- | $26.76M | $1.10M | $1.06M | $1.25M | $254.08M | $178.39M | $-31.00K | $826.00M | $1.49M | $1.28M | $1.95M | $1.23M | $1.73M | $1.18M | $2.12M | $904.00K |
| Purchases of Investments | $-333.63M | $-715.36M | $-284.87M | $-519.00M | $-417.71M | $-420.74M | $-244.08M | $-688.28M | $-261.98M | $-560.60M | $-200.34M | $-462.86M | $-193.23M | $-197.43M | $-410.67M | $-330.05M | $-193.78M | $-400.35M | $-431.91M | $-544.38M |
| Sales Maturities of Investments | $429.89M | $370.87M | $367.58M | $600.84M | $390.95M | $492.69M | $326.67M | $374.36M | $225.05M | $383.73M | $201.54M | $178.84M | $292.33M | $324.00M | $315.95M | $411.91M | $388.50M | $515.26M | $522.82M | $459.35M |
| Other Investing Activities | $-2.55M | $-2.51M | $- | $80.60M | $-27.53M | $-1.10M | $-1.06M | $-1.25M | $216.29M | $-178.39M | $31.00K | $-826.00M | $-1.49M | $-1.28M | $-1.95M | $-1.23M | $-1.73M | $-1.18M | $-2.12M | $-904.00K |
| Net Cash Used for Investing Activities | $68.21M | $-340.80M | $62.45M | $76.11M | $-26.71M | $68.71M | $69.52M | $-325.64M | $212.15M | $-183.93M | $-3.30M | $-287.55M | $95.11M | $121.97M | $-101.03M | $78.86M | $187.85M | $101.94M | $79.69M | $-95.01M |
| Debt Repayment | $-44.55M | $-48.00K | $-39.00K | $-39.00K | $-38.00K | $-67.83M | $154.81M | $-39.00K | $-50.60M | $-89.00K | $- | $- | $-61.97M | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $429.00K | $496.10M | $2.60M | $23.61M | $40.76M | $3.73M | $2.39M | $2.56M | $343.00K | $2.57M | $1.61M | $1.85M | $1.00K | $1.92M | $1.88M | $7.76M | $22.59M | $13.00M | $8.80M | $7.65M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.00K | $-90.55M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $496.10M | $- | $- | $40.76M | $31.84M | $-11.27M | $492.13M | $-765.00K | $-645.00K | $-399.00K | $-9.17M | $-524.00K | $-464.00K | $312.66M | $-15.34M | $-544.07M | $-2.06M | $-368.00K | $-11.60M |
| Net Cash Used Provided by Financing Activities | $-44.12M | $496.05M | $2.56M | $23.57M | $40.72M | $-32.27M | $143.54M | $492.09M | $-51.02M | $1.83M | $1.22M | $-7.33M | $-62.49M | $1.46M | $314.54M | $-7.58M | $-521.48M | $10.94M | $8.44M | $-94.50M |
| Effect of Forex Changes on Cash | $-486.00K | $350.00K | $-23.00K | $-114.00K | $330.00K | $-152.00K | $70.00K | $104.00K | $546.00K | $-399.00K | $-411.00K | $-154.00K | $-68.00K | $-21.00K | $104.00K | $-126.00K | $259.00K | $358.00K | $74.00K | $8.00K |
| Net Change in Cash | $-92.53M | $40.61M | $-54.90M | $-50.38M | $47.21M | $-72.73M | $115.76M | $32.56M | $-38.52M | $-206.92M | $-20.60M | $-326.68M | $236.24M | $67.83M | $150.96M | $16.49M | $-235.40M | $102.88M | $43.99M | $-197.09M |
| Cash at End of Period | $242.08M | $334.61M | $293.99M | $348.89M | $399.27M | $352.06M | $424.79M | $309.03M | $276.47M | $314.99M | $521.92M | $542.51M | $869.19M | $632.95M | $565.12M | $414.15M | $397.66M | $633.06M | $530.18M | $486.19M |
| Cash at Beginning of Period | $334.61M | $293.99M | $348.89M | $399.27M | $352.06M | $424.79M | $309.03M | $276.47M | $314.99M | $521.92M | $542.51M | $869.19M | $632.95M | $565.12M | $414.15M | $397.66M | $633.06M | $530.18M | $486.19M | $683.29M |
| Operating Cash Flow | $-116.14M | $-114.99M | $-119.88M | $-149.94M | $32.87M | $-109.02M | $-97.36M | $-133.99M | $-200.19M | $-24.43M | $-18.10M | $-31.65M | $203.69M | $-55.57M | $-62.65M | $-54.66M | $97.98M | $-10.36M | $-44.14M | $-7.58M |
| Capital Expenditure | $-28.04M | $6.21M | $-20.26M | $-5.73M | $819.00K | $-3.24M | $-13.07M | $-11.72M | $-5.01M | $-7.06M | $-4.50M | $-3.53M | $-3.99M | $-4.60M | $-6.31M | $-3.00M | $-6.87M | $-12.97M | $-11.22M | $-9.98M |
| Free Cash Flow | $-144.18M | $-111.30M | $-140.14M | $-155.67M | $33.68M | $-112.26M | $-110.44M | $-145.72M | $-205.20M | $-31.49M | $-22.60M | $-35.18M | $199.70M | $-60.17M | $-68.96M | $-57.66M | $91.10M | $-23.33M | $-55.36M | $-17.57M |
Ionis Pharmaceuticals Dividends
Explore Ionis Pharmaceuticals's dividend history, including dividend yield, payout ratio, and historical payments.
Ionis Pharmaceuticals News
Read the latest news about Ionis Pharmaceuticals, including recent articles, headlines, and updates.
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
OSAKA, Japan--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “ONO”) announced that it has entered into a license agreement with Ionis Pharmaceuticals, Inc. (Carlsbad, CA,U.S.; CEO, Brett P. Monia, Ph.D.; “Ionis”) for sapablursen, an investigational RNA-targeted medicine for the treatment of polycythemia vera (PV). Sapablursen is currently being evaluated in adult patients with PV in the fully enrolled Phase 2 IMPRSSION study. Sapablu.
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV), a rare and potentially life-threatening hematologic disease. Sapablursen is currently being evaluated in adults living.
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis and AstraZeneca's WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. WAINZUA is the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.
Ionis to present at upcoming investor conferences
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11, 2025 Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 U.
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organiz.
Ionis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2024 Earnings Conference Call February 19, 2025 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Kyle Jenne - Chief Global Product Strategy Officer Richard Geary - Chief Development Officer Elizabeth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Development and Operations Officer Conference Call Participants Michael Ulz - Morgan Stanley Jessica Fye - JPMorgan Chase & Co. Akash Tewari - Jefferies Yanan Zhu - Wells Fargo Securities Jay Olson - Oppenheimer & Co. Chi Fong - Bank of America Merrill Lynch Gary Nachman - Raymond James & Associates, Inc. Yaron Werber - TD Cowen Operator Good morning, and welcome to Ionis' Fourth Quarter and Full-Year 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA Approval
Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, but expansion into the larger sHTG market by 2025 is crucial for the company to reach profitability and satisfy analyst's estimates. Ionis has a strong cash position and a robust pipeline of over 40 RNA-targeted therapeutics, making it a compelling watch-list candidate.
Ionis Pharma Beats Expectations for Q4
Ionis Pharmaceuticals (IONS 0.44%), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the anticipated $135 million.
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis reports fourth quarter and full year 2024 financial results
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024. “With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Over the next three years, we expect three more.
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Ionis to hold fourth quarter and full year 2024 financial results webcast
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that b.
Amyloidosis Treatment Market Research by Treatment, Drug Class, End-User, and Region - Global Forecasts to 2034
The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased awareness and support programs, and strategic alliances and collaborations. The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased awareness and support programs, and strategic alliances and collaborations.
Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
– Accelerating value creation with numerous commercial, regulatory and pipeline milestones – – Ionis outlines clear path to sustained positive cash flow – CARLSBAD, Calif. , Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones expected in 2025.
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza for FCS positions Ionis as the first company to independently develop and launch an RNA-targeted therapy. Ionis forecasts that its pipeline, containing approximately 40 investigational drugs, could generate billions in peak sales, with four launches projected in the next three years.
FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood
On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can lead to acute pancreatitis (AP).
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease Indicated for adults with FCS regardless of genetically or clinically confirmed diagnosis TRYNGOLZA is the first of four independent launches planned over the next three years, pending approvals Ionis to host webcast today at 6:45pm ET CARLSBAD, Calif. , Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (sHTG) that can lead to potentially life-threatening acute pancreatitis (AP).
How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%
The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia – Chief Executive Officer Eugene Schneider – Chief Clinical Development Officer Kyle Jenne – Chief Global Product Strategy Officer Beth Hougen – Chief Financial Officer Jonathan Birchall – Chief Commercial Officer Eric Swayze – Executive Vice President of Research Richard Geary – Chief Development Officer Conference Call Participants Gary Nachman – Raymond James Jessica Fye – JPMorgan Avi Novick – Morgan Stanley Yanan Zhu – Wells Fargo Securities Luca Issi – RBC David Lebowitz – Citi Jason Gerberry – Bank of America Jay Olson – Oppenheimer Mani Foroohar – Leerink Andy Chen – Wolfe Research Operator Good morning and welcome to the Ionis Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for IONS.